Cadrenal Therapeutics Share Price Today

Cadrenal Therapeutics to present at Lytham Partners Fall 2026 investor conference

CEO Quang X. Pham to present at Lytham Partners Fall 2026 Investor Conference. Webcast scheduled for 10:15 am ET on Tuesday, September 29, 2026. Management will host virtual one-on-one meetings with investors. Pipeline includes CAD-1005 for HIT and CSA-AKI treatment. Tecarfarin seeks Rare Pediatric Disease Designation for Kawasaki disease.

Cadrenal aligns with FDA on Phase 3 protocol for CAD-1005 in HIT

Cadrenal Therapeutics aligned with FDA on Phase 3 protocol for CAD-1005. Primary endpoint measures SRA+ participants with worsening CTEs through Day 14. Trial uses placebo control with standard anticoagulation for both arms. CAD-1005 targets ~50,000 acute HIT cases annually in the U.S. Projected peak annual revenue opportunity is $2 billion.

Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million

Cadrenal Therapeutics reported a Q2 2026 net loss of $3.3 million, down from $3.7 million YoY, driven by lower R&D expenses of $0.7 million. Cash stood at $2.4 million at quarter-end but rose to $4.2 million following a $3.0 million private placement. The company is pursuing strategic partnerships for its cardiac care franchise.

Cadrenal unveils cardiac critical care franchise, seeks partners

Cadrenal Therapeutics has reorganized its clinical portfolio into a Cardiac Acute Critical Care Franchise, focusing on therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions. The company is seeking strategic partnerships for its late-stage assets, including the Phase 3-ready CAD-1005 and Tecarfarin, and the Phase 2-ready Frunexian IV. Recent Phase 2 data for CAD-1005 presented at the ISTH 2026 Congress demonstrated a greater than 25% absolute reduction in thrombotic events.

Cadrenal's CAD-1005 cuts thrombotic events by over 25% in Phase 2

Cadrenal Therapeutics presented Phase 2 data at ISTH 2026 showing CAD-1005 reduced thrombotic events by over 25% in HIT patients. The first randomized trial in this space showed a 50% event rate for CAD-1005 versus >75% for placebo, with no serious adverse events. The therapy holds Orphan Drug and Fast Track designations and targets a market with $2 billion in peak annual revenue.

Cadrenal Therapeutics announces up to $8.8M private placement

Cadrenal Therapeutics entered into a definitive agreement to raise up to $8.8 million through a private placement, issuing 960,000 shares and warrants. The proceeds will extend the cash runway into 2027 to support partnering opportunities for tecarfarin and CAD-1005.